Urokinase receptor interacts with α(v)β5 vitronectin receptor, promoting urokinase-dependent cell migration in breast cancer

Cancer Research

Volumn 59, Issue 20, 1999, Pages 5307-5314

  Carriero, Maria V ^a,b   Del Vecchio, Silvana ^b   Capozzoli, Monica ^b   Franco, Paola ^b   Fontana, Laura ^c   Zannetti, Antonella ^b   Botti, Gerardo ^b   D'Aiuto, Giuseppe ^b   Salvatore, Marco ^b   Stoppelli, M Patrizia ^c  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^c INSTITUTE OF GENETICS AND BIOPHYSICS ADRIANO BUZZATI TRAVERSO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

F ACTIN; INTEGRIN; PROTEIN KINASE C; UROKINASE; UROKINASE RECEPTOR; VITRONECTIN RECEPTOR;

ADULT; AGED; AMINO TERMINAL SEQUENCE; ARTICLE; BREAST CANCER; CANCER INVASION; CELL ADHESION; CELL INTERACTION; CELL MIGRATION; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOSKELETON; ENZYME ACTIVITY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; SIGNAL TRANSDUCTION;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; CELL MOVEMENT; FEMALE; HUMANS; INTEGRINS; MIDDLE AGED; PROTEIN KINASE C; RECEPTORS, CELL SURFACE; RECEPTORS, VITRONECTIN; TUMOR CELLS, CULTURED; URINARY PLASMINOGEN ACTIVATOR; VITRONECTIN;

EID: 0032698213     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (58)

1. Woodhouse, E. C., Chuaqui, R. F., and Liotta, L. A. General mechanism of metastasis. Cancer (Phila.), 80: 1529-1537, 1997.
2. Dano, K., Behrendt, N., Brunner, N., Ellis, V., Ploug, M., and Pyke, C. The urokinase receptor. Protein structure and role in plasminogen activation and cancer invasion. Fibrinolysis, 8: 189-203, 1994.
3. Bugge, T. H., Kombrinck, K. W., Xiao, Q., Holmback, K., Daugherty, C. C., Witte, D. P., and Degen, J. L. Growth and dissemination of Lewis Lung carcinoma in plasminogen deficient mice. Blood, 90: 4522-4531, 1997.
4. Shapiro, R. L., Duquette, J. G., Roses, D. F., Nunes, I., Harris, M. N., Kamino, H., Wilson, E. L., and Rifkin, D. B. Induction of primary cutaneous melanocytic neoplasms in urokinase-type plasminogen activator (uPA)-deficient and wild-type mice: cellular blue nevi invade but not progress to malignant melanoma in uPA-deficient animals. Cancer Res., 56: 3597-3604, 1996.
5. Kirchheimer, J. C., Woita, J., Christ, J., and Binder, R. R. Functional inhibition of endogenously produced urokinase decreases cell proliferation in a human melanoma cell line. Proc. Natl. Acad. Sci. USA, 86: 5424-5428, 1989.
6. Gyetko, M. R., Todd, R. F., III, Wilkinson, C. C., and Sitrin, R. G. The urokinase receptor is required for human monocyte chemotaxis in vitro. J. Clin. Invest., 93: 1380-1387, 1994.
7. Waltz, D. A., Sailor, L. Z., and Chapman, H. A. Cytokines induce urokinase-dependent adhesion of human myeloid cells: a regulatory role for plasminogen activator inhibitors. J. Clin. Invest., 91: 1541-1552, 1993.
8. Stoppelli, M. P., Corti, A., Soffientini, A., Cassani, G., Blasi, F., and Assoian, R. K. Differentiation-enhanced binding of the amino-terminal fragment of human urokinase plasminogen activator to a specific receptor on U937 monocytes. Proc. Natl. Acad. Sci. USA, 832: 4939-4943, 1985.
9. Wei, Y., Waltz, D. A., Rao, N., Drummend, R. J., Rosenberg, S., and Chapman, H. A Identification of the urokinase receptor as an adhesion receptor for vitronectin. J. Biol. Chem., 269: 32380-32388, 1994.
10. Busso, N., Masur, S. K., Lazega, D., Waxman, S., and Ossowski, L. Induction of cell migration by pro-urokinase binding to its receptor: possible mechanism for signal transduction in human epithelial cells. J. Cell. Biol., 126: 259-270, 1994.
11. Fibbi, G., Caldini, R., Chevanne, M., Pucci, M., Schiavone, N., Morbidelli, L., Parenti, A., Granger, H. J., Del Rosso, M., Ziche, M. Urokinase-dependent angiogenesis in vitro and diacylglycerol production are blocked by antisense oligonucleotides against the urokinase receptor. Lab. Invest., 78: 1109-1119, 1998.
12. Resnati, M., Guttinger, M., Valcamonica, S., Sidenius, N., Blasi, F., and Fazioli, F. Proteolytic cleavage of the urokinase receptor substitutes for the agonist-induced chemotactic effect. EMBO J., 15, 1572-1582, 1996.
13. hck activation state is a molecular switch between myelomonocytic cell motility and adherence. EMBO J., 18: 3013-3023, 1999.
14. Stahl, H., and Mueller, B. A. The urokinase-type plasminogen activator receptor, a GPI-linked protein, is localized in caveolae. J. Cell Biol., 129: 335-344, 1995.
15. 2-integrins, and Src kinases within a single receptor complex of human monocytes. J. Exp. Med., 181: 1381-1390, 1995.
16. Wei, Y., Lukashev, M., Simon, D. I., Bodary, S. C., Rosenberg, S., Doyle, M. V., and Chapman, H. A. Regulation of integrin function by the urokinase receptor. Science (Washington DC), 273: 1551-1555, 1996.
17. Myohanen, H. T., Stephens, R. W., Hedman, K., Tapiovaara, H., Ronne, E., Hoyer-Hansen, G., Dano, K., and Vaheri, A. Distribution and lateral mobility of the urokinase-receptor complex at the cell surface. J. Histochem. Cytochem., 41: 1291-1301, 1993.
18. 138/303 impairs receptor-dependent ability to promote myelomonocytic adherence and motility. J. Cell Biol., 137: 779-791, 1997.
19. Hynes, R. O. Integrins: versatility, modulation, and signaling in cell adhesion. Cell, 69: 11-25, 1992.
20. Clark, E. A., and Brugge, J. S. Integrins and signal transduction pathways: the road taken. Science (Washington DC), 268: 233-239, 1995.
21. Schwartz, M. A., Schaller, M. D., Ginsberg, M. H. Integrins: emerging paradigms of signal transduction. Annu. Rev. Cell Dev. Biol., 11: 549-599, 1995.
22. Schwartz, M. A. Integrins, oncogenes and anchorage-independence. J. Cell Biol., 139: 575-578, 1997.
23. Pignatelli, M., Cardillo, M. R., Hanby, A., and Stamp, G. W. H. Integrins and their accessory adhesion molecules in mammary carcinomas: loss of polarization in poorly differentiated tumors. Hum. Pathol., 23: 1159-1166, 1992.
24. Tang, H., Kerins, D. M., Hao, Q., Inagami, T., and Vaughan, D. E. The urokinase-type plasminogen activator receptor mediates tyrosine phosphorylation of focal adhesion proteins and activation of mitogen-activated protein kinase in cultured endothelial cells. J. Biol. Chem., 273: 18268-18272, 1998.
25. 3 integrins of fibrosarcoma cells: dependence on extracellular matrix components. Cancer Res., 57: 1682-1689, 1997.
26. Chapman, H. A. Plasminogen activators, integrins, and the coordinated regulation of cell adhesion and migration. Curr. Opin. Cell Biol., 9: 714-724, 1997.
27. Blasi, F. uPA, uPAR, PAI-1: key intersection of proteolytic, adhesive and chemotactic highways? Trends Immunol. Today, 18: 415-417, 1997.
28. Deng, G., Curriden, S. A., Wang, S., Rosenberg, S., and Loskutoff, D. J. Is plasminogen activator inhibitor-1 the molecular switch that governs urokinase receptor-mediated cell adhesion and release? J. Cell Biol., 134:1563-1571, 1996.
29. 3 binding to vitronectin. Nature (Lond.), 383: 441-443, 1996.
30. 5-mediated adhesion of a human keratynocyte cell line (HaCaT) to vitronectin. Exp. Cell Res., 220: 274-282, 1995.
31. 5-directed cell migration. J. Biol. Chem., 271: 29393-29399, 1996.
32. 3)-ligand interaction. J. Biol. Chem., 265: 2168-2172, 1990.
33. v integrins. Science (Washington DC), 270: 1500-1502, 1995.
34. 5-dependent cytoskeletal associations and focal adhesion kinase phosphorylation. J. Cell Biol., 134: 1323-1332, 1996.
35. Carriero, M. V., Franco, P., Del Vecchio, S., Massa, O., Botti, G., D'Aiuto, G., Stoppelli, M. P., and Salvatore, M. Tissue distribution of soluble and receptor-bound urokinase in human breast cancer using a panel of monoclonal antibodies. Cancer Res., 54: 5445-5454, 1994.
36. Carriero, M. V., Del Vecchio, S., Franco, P., Potena, M. I., Chiaradonna, F., Botti, G., Stoppelli, M. P., and Salvatore, M. Vitronectin binding to urokinase receptor in breast carcinoma. Clinical Cancer Res., 3: 1299-1308, 1997.
37. 2-terminal domain of the urokinase receptor. FEBS Lett., 288: 233-236, 1991.
38. 5 contribute to cell attachment to vitroneclin but differentially distribute on the cell surface. J. Cell Biol., 113: 919-929, 1991.
39. Freed, E., Gailit, J., Van Der Geer, P., Ruoslahti, E., and Hunter, T. A novel integrin β subunit is associated with the vitronectin receptor α subunit (αv) in a human osteosarcoma cell line and is a substrate for protein kinase C. EMBO J., 8: 2955-2965, 1989.
40. 3 integrin is present on human osteoclasts. Exp. Cell Res., 205: 345-352, 1993.
41. 3 (glycoprotein IIb-IIIa) in a variant of Glanzmann thrombasthenia. Proc. Natl. Acad. Sci. USA, 89: 10169-10173, 1992.
42. Roldan, A., Cubellis, M. V., Masucci, M. T., Beherendt, N., Lund, L. R., Dano, K., Appella, E., and Blasi, F. Cloning and expression of the receptor for human urokinase plasminogen activator, a central molecule in cell surface, plasmin dependent proteolysis. EMBO J., 9: 467-474, 1990.
43. Stoppelli, M. P., Tacchetti, C., Cubellis, M. V., Corti, A., Hearing, V. J., Cassani, G., Appella, E., and Blasi, F. Autocrine saturation of pro-urokinase receptors on human A431 cells. Cell, 45: 675-684, 1986.
44. Zutter, M. M., Krigman, H. R., and Santoro, S. A. Altered integrin expression in adenocarcinoma of the breast. Analysis by in situ hybridization. Am. J. Pathol., 142: 1439-1448, 1993.
45. Berdichevsky, F., Wetzels, R., Shearer, M., Maringnone, S., Ramaekers, F. C. S., and Taylor-Papdimitriou, J. Integrin expression in relation to cell-phenotype and malignant change in the human breast. Mol. Cell Diff., 2: 255-274, 1994.
46. 1 integrin abrogates the malignant phenotype of breast carcinoma cells. Proc. Natl. Acad. Sci. USA, 92: 7411-7415, 1995.
47. 4 integrin expression in breast carcinomas is affected by laminin production from tumor cells. Clin. Cancer Res., 4: 407-410, 1998.
48. Weaver, V. M., Petersen, O. W., Wang, F., Larabell, C. A., Briand, P., Damasky, C., and Bissell, M. J. Reversion of the malignant phenotype of human breast cells in three-dimensional culture and in vivo by integrin blocking antibodies. J. Cell Biol., 137: 231-245, 1997.
49. 3: a new prognostic indicator in breast cancer. Clin. Cancer Res., 4: 2625-2634, 1998.
50. Gui, G. P. H., Puddefoot, J. R., Vinson, G. P., Wells, C. A., and Carpenter, R. In vitro regulation of human breast cancer cell adhesion and invasion via integrin receptors to the extracellular matrix. Br. J. Surg., 82: 1192-1196, 1995.
51. Kindzelskii, A. L., Laska, Z. O., Todd, R. F., III, and Petty, H. R. Urokinase-type plasminogen activator reversibly dissociates from complement receptor type 3 (aMb2. CD11b/CD18) during neutrophil polarization. J. Immunol., 157: 297-309, 1996.
52. Brooks, P. C., Silletti, S., Von Schalscha, T. L., Friedlander, M., and Cheresh, D. A. Disruption of angiogenesis by PEX, a non catalytic metalloproteinase fragment with integrin binding activity. Cell, 92: 391-400, 1998.
53. Huttenlocher, A., Sandborg, R. R., and Horwitz, A. F. Adhesion in cell migration. Curr. Opin. Cell Biol., 7: 697-706, 1995.
54. Del Vecchio, S., Stoppelli, M. P., Carriero, M. V., Fonti, R., Massa, O., Li, P. Y., Botti, G., Cerra, M., D'Aiuto, G., Esposito, G., and Salvatore, M. Human urokinase receptor concentration in malignant and benign breast tumors by in vitro quantitative autoradiography: comparison with urokinase levels. Cancer Res., 53: 3198-3206, 1993.
55. Andreasen, P. A., Kjoller, L., Christensen, L., and Duffy, M. J. The urokinase-type plasminogen activator system in cancer metastasis: a review. Int. J. Cancer, 72: 1-22, 1997.
56. Fazioli, F., and Blasi, F. Urokinase-type plasminogen activator and its receptor: new targets for anti-metastatic therapy? Trends Pharmacol. Sci., 15: 25-29, 1994.
57. Min, H. Y., Doyle, L. V., Vitt., C. R., Zandonella, C. L., Stratton-Thomas, J. R., Shuman, M. A., and Rosenberg, S. Urokinase receptor antagonists inhibit angiogenesis and primary tumor growth in syngenic mice. Cancer Res., 56: 2428-2434, 1996.
58. Franco, P., Massa, O., Garcia-Rocha, M., Chiaradonna, F., Iaccarino, C., Correas, I., Mendez, E., Avila, J., Blasi, F., and Stoppelli, M. P. Protein kinase C-dependent in vivo phosphorylation of prourokinase leads to the formation of a receptor competitive antagonist. J. Biol. Chem., 273: 27734-27740, 1998.